Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
18F-Fdg Pet/Mri and 18F-Fdg Pet/Ct for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature Publisher



Allahqoli L1 ; Hakimi S2 ; Lagana AS3 ; Momenimovahed Z4 ; Mazidimoradi A5 ; Rahmani A6 ; Fallahi A7 ; Salehiniya H8 ; Ghiasvand MM9 ; Alkatout I10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Ministry of Health and Medical Education, Tehran, 1467664961, Iran
  2. 2. Faculty of Nursing and Midwifery, Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, 516615731, Iran
  3. 3. Unit of Obstetrics and Gynecology, “Paolo Giaccone� Hospital, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 90127, Italy
  4. 4. Department of Midwifery and Reproductive Health, Qom University of Medical Sciences, Qom, 3716993456, Iran
  5. 5. Neyriz Public Health Clinic, Shiraz University of Medical Sciences, Shiraz, 7134845794, Iran
  6. 6. Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, 141973317, Iran
  7. 7. Department of Public Health, Faculty of Health, Kurdistan University of Medical Sciences, Sanandaj, 6617713446, Iran
  8. 8. Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, 9717853076, Iran
  9. 9. Department of Computer Engineering, Amirkabir University of Technology (AUT), Tehran, 1591634311, Iran
  10. 10. University Hospitals Schleswig-Holstein, Kiel School of Gynaecological Endoscopy, Campus Kiel, Arnold-Heller-Str. 3, Haus 24, Kiel, 24105, Germany

Source: Journal of Imaging Published:2023


Abstract

Objective: Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro- D-glucose integrated with computed tomography (18F-FDG PET/CT) or magnetic resonance imaging (18F-FDG PET/MRI) has emerged as a promising tool for managing various types of cancer. This review study was conducted to investigate the role of 18F- FDG PET/CT and FDG PET/MRI in the management of gynecological malignancies. Search strategy: We searched for relevant articles in the three databases PubMed/MEDLINE, Scopus, and Web of Science. Selection criteria: All studies reporting data on the FDG PET/CT and FDG PET MRI in the management of gynecological cancer, performed anywhere in the world and published exclusively in the English language, were included in the present study. Data collection and analysis: We used the EndNote software (EndNote X8.1, Thomson Reuters) to list the studies and screen them on the basis of the inclusion criteria. Data, including first author, publication year, sample size, clinical application, imaging type, and main result, were extracted and tabulated in Excel. The sensitivity, specificity, and diagnostic accuracy of the modalities were extracted and summarized. Main results: After screening 988 records, 166 studies published between 2004 and 2022 were included, covering various methodologies. Studies were divided into the following five categories: the role of FDG PET/CT and FDG-PET/MRI in the management of: (a) endometrial cancer (n = 30); (b) ovarian cancer (n = 60); (c) cervical cancer (n = 50); (d) vulvar and vagina cancers (n = 12); and (e) gynecological cancers (n = 14). Conclusions: FDG PET/CT and FDG PET/MRI have demonstrated potential as non-invasive imaging tools for enhancing the management of gynecological malignancies. Nevertheless, certain associated challenges warrant attention. © 2023 by the authors.